Non-Small Cell Lung Cancer Coverage from Every Angle
Advertisement
Advertisement

Wallace Akerley, MD, and David S. Ettinger, MD: Biomarker-Based Treatment Selection

Posted: Thursday, March 23, 2017

Wallace Akerley, MD, of the Huntsman Cancer Institute at the University of Utah, and David S. Ettinger, MD, of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, discuss different biomarkers for which effective targeted treatment is available and sequencing of systemic therapy for patients with metastatic non–small cell lung cancer, EGFR mutations, and ALK and ROS1 gene rearrangements.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.